Bayer AGXSWX:BAYN +3.59%35 Earnings Yield (Joel Greenblatt) % is 0.25% as of Mar. 2026, which is 96% below its 10-year median of 6.26. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF24.67 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,016 Drug Manufacturers companies, Bayer AG ranks worse than 66.54% on this metric.
Bayer AG's Enterprise Value for the quarter that ended in Mar. 2026 was CHF28,990 Mil.
Bayer AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-5 Mil. Bayer AG's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 0.25%.
The historical rank and industry rank for Bayer AG's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XSWX:BAYN'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -69.4 Med: 6.26 Max: 19.34
Current: 0.1
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Bayer AG was 19.34%. The lowest was -69.40%. And the median was 6.26%.
XSWX:BAYN's Earnings Yield (Joel Greenblatt) % is ranked worse than 66.54% of 1016
companies
in the Drug Manufacturers industry
Industry Median: 3.24
vs XSWX:BAYN: 0.10
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Bayer AG's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Bayer AG (XSWX:BAYN) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Bayer AG Earnings Yield (Joel Greenblatt) % Related Terms
Bayer AG Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Bayer AG's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bayer AG's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Bayer AG's Earnings Yield (Joel Greenblatt) % falls into.
Bayer AG Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Bayer AGs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Bayer AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-5 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 0.25% mean?
Bayer AG (XSWX:BAYN) has a Earnings Yield (Joel Greenblatt) % of 0.25% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Bayer AG and its competitors. This is 96% below median its historical median of 6.26. According to the industry distribution chart, Bayer AG ranks #676 out of 1016 companies in the Drug Manufacturers industry, placing it in the top 66.5%.
Is Bayer AG's Earnings Yield (Joel Greenblatt) % too high?
Bayer AG's current Earnings Yield (Joel Greenblatt) % of 0.25% is 96% below median its 10-year median of 6.26. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.24. Bayer AG's value of 0.25% is 92.3% below this industry median. Based on the distribution chart, Bayer AG ranks #676 out of 1016 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Earnings Yield (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #676 out of 1016 companies for Earnings Yield (Joel Greenblatt) %. This places Bayer AG in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.24. Bayer AG's value of 0.25% is 92.3% below this benchmark. While the company's 10-year median is 6.26 vs. the industry median of 3.24, Bayer AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.24, based on 1,016 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current Earnings Yield (Joel Greenblatt) % of 0.25% is 92.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current Earnings Yield (Joel Greenblatt) % is 0.25%, which is 96% below median its own 10-year median of 6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.67, compared to a current price of CHF47.36 — trading 92% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.25%, which is 96% below median its 10-year median of 6.26 and 92.3% below the Drug Manufacturers industry median of 3.24. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Earnings Yield (Joel Greenblatt) % is 0.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF47.36 is trading 92% above its estimated GF Value™ of CHF24.67.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
Earnings Yield (Joel Greenblatt) %: 0.25% (96% below median its 10-year median of 6.26)
GF Value™: CHF24.67 vs. price of CHF47.36 (92% above fair value)
Industry Position: 92.3% below the Drug Manufacturers median (#676 of 1016)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score
Get the complete analysis for XSWX:BAYN
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
